Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04066114 · ClinicalTrials.gov registry record · Phase 1
Treg Modulation With CD28 and IL-6 Receptor Antagonists
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04066114 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants.
The verdict
NCT04066114, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.
Interventions
- DRUG Prednisone
- DRUG methylprednisolone
- BIOLOGICAL tocilizumab
- BIOLOGICAL lulizumab pegol
- BIOLOGICAL antithymocyte globulin (rabbit)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2023-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04066114
The ClinicalTrials.gov registry entry for NCT04066114 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Prednisone is the first listed.
NCT04066114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04066114 about?
NCT04066114 is a clinical study titled "Treg Modulation With CD28 and IL-6 Receptor Antagonists". The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.
What is the current status of trial NCT04066114?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-12-11. Estimated completion is 2023-09-14.
What interventions are being tested in trial NCT04066114?
The interventions under investigation include: Prednisone (DRUG), methylprednisolone (DRUG), tocilizumab (BIOLOGICAL), lulizumab pegol (BIOLOGICAL), antithymocyte globulin (rabbit) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04066114?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.